ASLAN Pharmaceuticals’ (ASLN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of ASLAN Pharmaceuticals (NASDAQ:ASLN) in a report released on Tuesday morning, Benzinga reports. The firm currently has a $9.00 target price on the stock.

Separately, Piper Sandler restated an overweight rating and set a $10.00 price objective (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a report on Wednesday, March 13th.

ASLAN Pharmaceuticals Stock Up 3.1 %

ASLN opened at $0.47 on Tuesday. ASLAN Pharmaceuticals has a 52-week low of $0.39 and a 52-week high of $4.69. The company has a market cap of $7.67 million, a P/E ratio of -0.17 and a beta of 1.45. The firm’s 50-day moving average price is $0.61 and its 200-day moving average price is $0.72.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last posted its quarterly earnings data on Friday, April 12th. The company reported ($0.78) earnings per share (EPS) for the quarter. On average, research analysts anticipate that ASLAN Pharmaceuticals will post -2.68 EPS for the current fiscal year.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.